RachelB.WagmanMDFACE, FACP

PubMed

• 3 citations
  Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials.
  Elizabeth A Stewart, Andrea S Lukes, Roberta Venturella, Yulan Li, Elke Hunsche, Rachel B Wagman, Ayman Al-Hendy> ;American Journal of Obstetrics and Gynecology. 2023 Mar 1
• 37 citations
  Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (...
  Linda C Giudice, Sawsan As-Sanie, Juan C Arjona Ferreira, Christian M Becker, Mauricio S Abrao, Bruce A Lessey, Eric Brown, Krzysztof Dynowski, Krzysztof Wilk, Yulan L...> ;Lancet. 2022 Jun 18
• 66 citations
  Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy.
  Ayman Al-Hendy, Andrea S. Lukes, Alfred N. Poindexter, Roberta Venturella, Claudio Villarroel, Hilary O. D. Critchley, Yulan Li, Laura McKain, Juan Camilo Arjona Ferre...> ;The New England Journal of Medicine. 2021 Feb 18
• 26 citations
  Modeling-Based Bone Formation in the Human Femoral Neck in Subjects Treated With Denosumab
  David W. Dempster, Arkadi Chines, Mathias P.G. Bostrom, Jeri W. Nieves, Hua Zhou, Li Chen, Nico Pannacciulli, Rachel B. Wagman, Felicia Cosman> ;Journal of Bone and Mineral Research. 2020 Mar 12
• 17 citations
  Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment.
  Serge Ferrari, Peter W. Butler, David L. Kendler, Paul D. Miller, Christian Roux, A. Wang, Shuang Huang, Rachel B. Wagman, E. Michael Lewiecki> ;The Journal of Clinical Endocrinology and Metabolism. 2019 Aug 1
• 65 citations
  Relationship Between Bone Mineral Density T-Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment
  Serge Ferrari, Cesar Libanati, Celia Jow Fang Lin, Jacques P. Brown, Felicia Cosman, Edward Czerwiński, L. H. de Gregόrio, J. Malouf-Sierra, Jean-Yves Reginster, A. Wa...> ;Journal of Bone and Mineral Research. 2019 Jun 1
• 39 citations
  Invasive Oral Procedures and Events in Postmenopausal Women With Osteoporosis Treated With Denosumab for Up to 10 Years
  Nelson B. Watts, John T. Grbic, Neil Binkley, S. Papapoulos, Peter W. Butler, Xiang Yin, Antoniette Tierney, Rachel B. Wagman, Michael R. McClung> ;The Journal of Clinical Endocrinology and Metabolism. 2019 Jun 1
• 10 citations
  Reduction of Cortical Bone Turnover and Erosion Depth After 2 and 3 Years of Denosumab: Iliac Bone Histomorphometry in the FREEDOM Trial
  Pascale Chavassieux, Nathalie Portero-Muzy, Jean-Paul Roux, Stéphane Horlait, David W. Dempster, Andrea Wang, Rachel B. Wagman, Roland Chapurlat> ;Journal of Bone and Mineral Research. 2019 Apr 1
• 52 citations
  Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis.
  David W. Dempster, Jacques P. Brown, Astrid Fahrleitner-Pammer, David L. Kendler, Sébastien Rizzo, Ivo Valter, Rachel B. Wagman, Xiang Yin, Susan V Yue, Georges Boivin> ;The Journal of Clinical Endocrinology and Metabolism. 2018 Jul 1
• 110 citations
  Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study
  Kenneth G. Saag, Rachel B. Wagman, Piet Geusens, Jonathan D. Adachi, Osvaldo D. Messina, Ronald Emkey, Roland Chapurlat, Andrea Wang, Nicola Pannacciulli, Willem F. Lems> ;The Lancet. Diabetes & Endocrinology. 2018 Jun 1
• 31 citations
  Effect of denosumab on fasting glucose in women with diabetes or prediabetes from the FREEDOM trial.
  Nicola Napoli, Nicola Pannacciulli, Eric Vittinghoff, Daria B. Crittenden, Jang Yun, Andrea Wang, Rachel B. Wagman, Ann V. Schwartz> ;Diabetes/metabolism Research and Reviews. 2018 May 1
• 5 citations
  Denosumab treatment in postmenopausal women with osteoporosis - Authors' reply
  Henry G. Bone, Rachel B. Wagman, Nicola Pannacciulli, Socrates E. Papapoulos> ;The Lancet. Diabetes & Endocrinology. 2017 Oct 1
• 56 citations
  The Ability of a Single BMD and Fracture History Assessment to Predict Fracture Over 25 Years in Postmenopausal Women: The Study of Osteoporotic Fractures.
  Dennis M. Black, Jane A. Cauley, Rachel B. Wagman, Kristine E. Ensrud, Howard A Fink, Teresa A. Hillier, Li Yung Lui, Steven R. Cummings, John T. Schousboe, Nicola Napoli> ;Journal of Bone and Mineral Research. 2018 Mar 1
• 478 citations
  10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
  Henry G. Bone, Rachel B. Wagman, Maria Luisa Brandi, Jacques P. Brown, Roland Chapurlat, Steven R. Cummings, Edward Czerwiński, Astrid Fahrleitner-Pammer, David L. Ken...> ;The Lancet. Diabetes & Endocrinology. 2017 Jul 1
• 11 citations
  Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study
  Jonathan D. Adachi, Henry G. Bone, Nadia Daizadeh, P. Dakin, S. Papapoulos, Peyman Hadji, Chris Recknor, Michael A. Bolognese, Andrea Wang, Celia J. F. Lin, Rachel B. ...> ;BMC Musculoskeletal Disorders. 2017 Apr 27
• 14 citations
  Safety Observations With 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed...
  Nelson B. Watts, Jacques P. Brown, S. Papapoulos, E. Michael Lewiecki, David L. Kendler, P. Dakin, Rachel B. Wagman, Andrea Wang, Nadia Daizadeh, S. Smith, Henry G. Bone> ;Journal of Bone and Mineral Research. 2017 Jul 1
• 138 citations
  Observations following discontinuation of long-term denosumab therapy.
  Michael R. McClung, Rachel B. Wagman, Paul Miller, Andrea Wang, E. M. Lewiecki> ;Osteoporosis International. 2017 Jan 31
• Response to the Letter: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or ...
  Paul D. Miller, Nico Pannacciulli, Rachel B. Wagman, Steven R. Cummings> ;The Journal of Clinical Endocrinology and Metabolism. 2016 Sep 7
• 134 citations
  Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates.
  Paul D. Miller, Nicola Pannacciulli, Jacques P. Brown, Edward Czerwiński, Bettina S. Nedergaard, M. A. Bolognese, Jorge Malouf, Henry G. Bone, Jean-Yves Reginster, A. ...> ;The Journal of Clinical Endocrinology and Metabolism. 2016 Jun 6
• 186 citations
  The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study
  S. Papapoulos, Kurt Lippuner, C. Roux, C J F Lin, David L. Kendler, E. M. Lewiecki, M. L. Brandi, Edward Czerwiński, Edward Franek, Peter L. Lakatos, Carlos Mautalen, ...> ;Osteoporosis International. 2015 Jul 23
• 73 citations
  Sustained Modeling‐Based Bone Formation During Adulthood in Cynomolgus Monkeys May Contribute to Continuous BMD Gains With Denosumab
  Michael S. Ominsky, Cesar Libanati, Qing-Tian Niu, Rogely W. Boyce, Paul J. Kostenuik, Rachel B. Wagman, Roland Baron, David W. Dempster> ;Journal of Bone and Mineral Research. 2015 Jul 1
• 58 citations
  Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after...
  Serge Ferrari, Jonathan D. Adachi, Kurt Lippuner, C. Zapalowski, Paul D. Miller, Jacques Reginster, Ove Tørring, David L. Kendler, Nadia Daizadeh, A. Wang, Cynthia D. ...> ;Osteoporosis International. 2015 Jun 12
• 18 citations
  Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis
  Santiago Palacios, L. Kalouche-Khalil, René Rizzoli, C. Zapalowski, Heinrich Resch, Jonathan D. Adachi, J. C. Gallagher, R. G. Feldman, David L. Kendler, A. Wang, Rach...> ;Climacteric. 2015 Jun 1
• 10 citations
  Fracture incidence in a large cohort of men age 30 years and older with osteoporosis.
  A. D. Manthripragada, Cynthia D. O'Malley, Ugis Gruntmanis, J. W. Hall, Rachel B. Wagman, Paul D. Miller> ;Osteoporosis International. 2015 Jan 24
• 68 citations
  A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial.
  Bente L. Langdahl, Christence S. Teglbjaerg, P.R. Ho, Roland Chapurlat, Edward Czerwiński, David L. Kendler, Jean-Yves Reginster, Alan Kivitz, E. Michael Lewiecki, Pau...> ;The Journal of Clinical Endocrinology and Metabolism. 2015 Jan 21
• Join now to see all